bioAffinity Technologies Earnings Call Transcripts
Fiscal Year 2026
-
The conference showcased advances in noninvasive diagnostics, with a focus on early lung cancer detection. CyPath Lung demonstrated strong clinical performance and rapid adoption, with plans to expand into asthma and COPD diagnostics.
-
Pulmonary nodule assessment faces rising complexity due to increased screening and variable risk profiles. CyPath Lung offers a non-invasive, highly sensitive risk stratification tool that aids in clinical decision-making, reduces unnecessary procedures, and alleviates patient anxiety. Its adoption is growing among clinicians for both initial and follow-up management.
Fiscal Year 2024
-
Record sales and revenue growth in 2024 were driven by CyPath Lung, with national expansion underway and a pivotal FDA trial set for 2025. The company is leveraging strong leadership, a robust pipeline, and increased physician adoption to target further growth and profitability.
-
A novel flow cytometry-based lung cancer test demonstrated high accuracy and rapid, patient-friendly results, with strong reimbursement and recent inclusion in the Federal Supply Schedule. Expansion beyond Texas and into VA/military systems is planned, with FDA trials and new indications in development.